AKB-6548

DRUG6 trials

Sponsors

Akebia Therapeutics

Conditions

AnemiaChronic Kidney DiseaseEnd Stage Renal DiseaseHealthy VolunteersKidney Disease

Phase 1

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

CompletedNCT02327546

Akebia TherapeuticsHealthy Volunteers

Start: 2014-12-31End: 2015-02-28Updated: 2018-11-14

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

CompletedNCT02502500

Akebia TherapeuticsHealthy Volunteers

Start: 2015-07-31End: 2015-09-30Updated: 2018-11-14

Phase 2

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

CompletedNCT01235936

Akebia TherapeuticsAnemia, Kidney Disease

Start: 2010-10-21End: 2011-05-31Updated: 2022-07-01

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

CompletedNCT01381094

Akebia TherapeuticsAnemia, Kidney Disease

Start: 2011-06-15End: 2012-02-16Updated: 2022-07-01

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

CompletedNCT01906489

Akebia TherapeuticsAnemia, Chronic Kidney Disease

Start: 2013-07-23End: 2014-09-03Updated: 2022-07-21

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

CompletedNCT02260193

Akebia TherapeuticsAnemia, End Stage Renal Disease

Start: 2014-09-10End: 2015-07-22Updated: 2022-07-01

Related Papers

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.

2017-03-25104 citations

PowerPoint Slides for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

Figshare2017-01-01